Pegozafermin Led to Significant Metabolic Benefits, in Addition to Robust Beneficial Effects on the Liver, in an Open-label Cohort of a Phase 1b/2a Study in Subjects with Non-alcoholic Steatohepatitis (NASH) - Alkhouri, Naim; Loomba, Rohit; Frias, Juan P.; Feng, Shibao; Tseng, Leo; Agollah, Germaine D.; Mansbach, Hank; Margalit, Maya; Hartsfield, Cynthia L.; Harrison, Stephen (Metabolism, clinical and experimental, 2023)